Daan Gene Co., Ltd. (SHE:002030)

China flag China · Delayed Price · Currency is CNY
6.88
-0.42 (-5.75%)
May 12, 2026, 3:04 PM CST
Market Cap10.25B +33.2%
Revenue (ttm)737.96M -10.4%
Net Income-895.46M
EPS-0.63
Shares Out1.40B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume248,297,173
Average Volume31,385,240
Open6.18
Previous Close7.30
Day's Range6.18 - 7.79
52-Week Range5.68 - 8.20
Beta0.30
RSI76.60
Earnings DateAug 28, 2026

About Daan Gene

Daan Gene Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables in China. It operates through two segments, Biological Products and Related Business and Financial Business. The company offers reagents for hepatitis virus, sexually transmitted infections, blood screening, digestive pathogens, coronavirus disease (COVID-19), pharmacogenomics, viral transport medium, human papillomavirus, human immunodeficiency virus, respiratory infections, publi... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1988
Employees 1,730
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002030
Full Company Profile

Financial Performance

In 2025, Daan Gene's revenue was 757.66 million, a decrease of -11.18% compared to the previous year's 853.02 million. Losses were -744.38 million, -19.54% less than in 2024.

Financial Statements